|
1
|
Chen JJ, Zhang JX, Zhang XQ, Qi MJ, Shi
MZ, Yang J, Zhang KZ, Guo C and Han YL: Effects of diosmetin on
nine cytochrome P450 isoforms, UGTs and three drug transporters in
vitro. Toxicol Appl Pharmacol. 334:1–7. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tang S, Chen A, Zhou X, Zeng L, Liu M and
Wang X: Assessment of the inhibition risk of shikonin on cytochrome
P450 via cocktail inhibition assay. Toxicol Lett. 281:74–83. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lin JH: CYP induction-mediated drug
interactions: In vitro assessment and clinical implications. Pharm
Res. 23:1089–1116. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lu J, Shao Y, Qin X, Liu D, Chen A, Li D,
Liu M and Wang X: CRISPR knockout rat cytochrome P450 3A1/2 model
for advancing drug metabolism and pharmacokinetics research. Sci
Rep. 7:429222017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Xie B, Lu YY, Luo ZH, Qu Z, Zheng CG,
Huang XA, Zhou HY, Hu YJ and Shen XL: Tenacigenin B ester
derivatives from Marsdenia tenacissima actively inhibited CYP3A4
and enhanced in vivo antitumor activity of paclitaxel. J
Ethnopharmacol. 235:309–319. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rendic S and Guengerich FP: Survey of
human oxidoreductases and cytochrome P450 enzymes involved in the
metabolism of xenobiotic and natural chemicals. Chem Res Toxicol.
28:38–42. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wanwimolruk S and Prachayasittikul V:
Cytochrome P450 enzyme mediated herbal drug interactions (Part 1).
EXCLI J. 13:347–391. 2014.PubMed/NCBI
|
|
8
|
Jin C, Kim MH, Bang J and Serebruany V: A
prospective, randomized, open-label, blinded, endpoint study
exploring platelet response to half-dose prasugrel and ticagrelor
in patients with the acute coronary syndrome: HOPE-TAILOR study.
Cardiology. 138:201–206. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Vyas A, Bash LD, Patel MD and Simpson RJ
Jr: Changes in treatment patterns and incremental health care
utilization due to P2Y12-associated complications in patients with
acute coronary syndrome. J Manag Care Spec Pharm. 23:947–956.
2017.PubMed/NCBI
|
|
10
|
Amsterdam EA, Wenger NK, Brindis RG, Casey
DE Jr, Ganiats TG, Holmes DR Jr, Jaffe AS, Jneid H, Kelly RF,
Kontos MC, et al: 2014 AHA/ACC guideline for the management of
patients with non-ST-elevation acute coronary syndromes: Executive
summary: A report of the american college of cardiology/american
heart association task force on practice guidelines. Circulation.
130:2354–2394. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hamm CW, Bassand JP, Agewall S, Bax J,
Boersma E, Bueno H, Caso P, Dudek D, Gielen S, Huber K, et al: ESC
Guidelines for the management of acute coronary syndromes in
patients presenting without persistent ST-segment elevation: The
Task Force for the management of acute coronary syndromes (ACS) in
patients presenting without persistent ST-segment elevation of the
European Society of Cardiology (ESC). Eur Heart J. 32:2999–3054.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Task Force on the management of ST-segment
elevation acute myocardial infarction of the European Society of
Cardiology (ESC), ; Steg PG, James SK, Atar D, Badano LP,
Blömstrom-Lundqvist C, Borger MA, Di Mario C, Dickstein K, Ducrocq
G, et al: ESC Guidelines for the management of acute myocardial
infarction in patients presenting with ST-segment elevation. Eur
Heart J. 33:2569–2619. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wallentin L, Becker RC, Budaj A, Cannon
CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, et
al: Ticagrelor versus clopidogrel in patients with acute coronary
syndromes. N Engl J Med. 361:1045–1057. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Teng R, Mitchell PD and Butler KA:
Pharmacokinetic interaction studies of co-administration of
ticagrelor and atorvastatin or simvastatin in healthy volunteers.
Eur J Clin Pharmacol. 69:477–487. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhou D, Andersson TB and Grimm SW: In
vitro evaluation of potential drug-drug interactions with
ticagrelor: Cytochrome P450 reaction phenotyping, inhibition,
induction, and differential kinetics. Drug Metab Dispos.
39:703–710. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ancrenaz V, Deglon J, Samer C, Staub C,
Dayer P, Daali Y and Desmeules J: Pharmacokinetic interaction
between prasugrel and ritonavir in healthy volunteers. Basic Clin
Pharmacol Toxicol. 112:132–137. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ramasamy S, Kiew LV and Chung LY:
Inhibition of human cytochrome P450 enzymes by Bacopa monnieri
standardized extract and constituents. Molecules. 19:2588–2601.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Umemura K and Iwaki T: The
pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel
in healthy Japanese volunteers. Clin Pharmacol Drug Dev. 5:480–487.
2016. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Teng R, Hammarberg M, Carlson GF,
Bokelund-Singh S, Ruderfelt T and Blychert E: Pharmacokinetic
profiles of ticagrelor orodispersible tablets in healthy western
and Japanese Subjects. Clin Drug Investig. 37:1035–1045. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Savarese G and Lund LH: Ticagrelor versus
prasugrel in patients with acute coronary syndrome undergoing
percutaneous coronary intervention: An unresolved issue. Int J
Cardiol. 249:77–78. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lodola A: Developing combination drugs in
preclinical studies. Methods Mol Biol. 691:3–16. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhi D, Feng PF, Sun JL, Guo F, Zhang R,
Zhao X and Li BX: The enhancement of cardiac toxicity by
concomitant administration of Berberine and macrolides. Eur J Pharm
Sci. 76:149–155. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Farid NA, Small DS, Payne CD, Jakubowski
JA, Brandt JT, Li YG, Ernest CS, Salazar DE, Konkoy CS and Winters
KJ: Effect of atorvastatin on the pharmacokinetics and
pharmacodynamics of prasugrel and clopidogrel in healthy subjects.
Pharmacotherapy. 28:1483–1494. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhou S, Yung Chan S, Cher Goh B, Chan E,
Duan W, Huang M and McLeod HL: Mechanism-based inhibition of
cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet.
44:279–304. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lehmann JM, McKee DD, Watson MA, Willson
TM, Moore JT and Kliewer SA: The human orphan nuclear receptor PXR
is activated by compounds that regulate CYP3A4 gene expression and
cause drug interactions. J Clin Invest. 102:1016–1023. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ojeifo O, Wiviott SD, Antman EM, Murphy
SA, Udell JA, Bates ER, Mega JL, Sabatine MS and O'Donoghue ML:
Concomitant administration of clopidogrel with statins or
calcium-channel blockers: Insights from the TRITON-TIMI 38 (trial
to assess improvement in therapeutic outcomes by optimizing
platelet inhibition with prasugrel-thrombolysis in myocardial
infarction 38). JACC Cardiovasc Interv. 6:1275–1281. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Holmberg MT, Tornio A, Hyvarinen H,
Neuvonen M, Neuvonen PJ, Backman JT and Niemi M: Effect of
grapefruit juice on the bioactivation of prasugrel. Br J Clin
Pharmacol. 80:139–145. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang ZY, Chen M, Zhu LL, Yu LS, Zeng S,
Xiang MX and Zhou Q: Pharmacokinetic drug interactions with
clopidogrel: updated review and risk management in combination
therapy. Ther Clin Risk Manag. 11:449–467. 2015.PubMed/NCBI
|
|
30
|
Ju A, Li YY, Qu Z and Li Q: Impact of the
herbal breviscapine on the pharmacokinetics of simvastatin in rats:
The involvement of CYP3A4. Drug Res (Stuttg). 67:271–274. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Shu N, Hu M, Ling Z, Liu P, Wang F, Xu P,
Zhong Z, Sun B, Zhang M, Li F, et al: The enhanced atorvastatin
hepatotoxicity in diabetic rats was partly attributed to the
upregulated hepatic Cyp3a and SLCO1B1. Sci Rep. 6:330722016.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Dinicolantonio JJ and Serebruany VL:
Exploring the ticagrelor-statin interplay in the PLATO trial.
Cardiology. 124:105–107. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Huan JY, Streicher JM, Bleyle LA and Koop
DR: Proteasome-dependent degradation of cytochromes P450 2E1 and
2B1 expressed in tetracycline-regulated HeLa cells. Toxicol Appl
Pharmacol. 199:332–343. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liao M, Faouzi S, Karyakin A and Correia
MA: Endoplasmic reticulum-associated degradation of cytochrome P450
CYP3A4 in Saccharomyces cerevisiae: Further characterization of
cellular participants and structural determinants. Mol Pharmacol.
69:1897–1904. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Feng PF, Zhao L, Guo F, Zhang B, Fang L,
Zhan G, Xu X, Fang Q, Liang Z and Li B: The enhancement of
cardiotoxicity that results from inhibiton of CYP 3A4 activity and
hERG channel by berberine in combination with statins. Chem Biol
Interact. 293:115–123. 2018. View Article : Google Scholar : PubMed/NCBI
|
